CoChat

Aptamers: A promising chemical antibody for cancer therapy

Open access
Zhou, Gang, Wilson, George, Hebbard, Lionel, Duan, Wei, Liddle, Christopher, George, Jacob, Qiao, Liang · 2016 · Oncotarget
Cited by 134

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

// Gang Zhou 1 , George Wilson 1 , Lionel Hebbard 2 , Wei Duan 3 , Christopher Liddle 1 , Jacob George 1 and Liang Qiao 1 1 Storr Liver Centre, Westmead Millennium Institute for Medical Research, University of Sydney and Westmead Hospital, Westmead, NSW, Australia 2 Discipline of Molecular and Cell Biology, James Cook University, Townsville, QLD, Australia 3 School of Medicine, Deakin University, Waurn Ponds, VIC, Australia Correspondence to: Liang Qiao, email: // Wei Duan, email: // Keywords : aptamers, SELEX, siRNA, cancers, target therapy Received : October 25, 2015 Accepted : January 24, 2016 Published : February 03, 2016 Abstract Aptamers, also known as chemical antibodies, are single-stranded nucleic acid oligonucleotides which bind to their targets with high specificity and affinity. They are typically selected by repetitive in vitro process termed systematic evolution of ligands by exponential enrichment (SELEX). Owing to their excellent properties compared to conventional antibodies, notably their smaller physical size and lower immunogenicity and toxicity, aptamers have recently emerged as a new class of agents to deliver therapeutic drugs to cancer cells by targeting specific cancer-associated hallmarks. Aptamers can also be structurally modified to make them more flexible in order to conjugate other agents such as nano-materials and therapeutic RNA agents, thus extending their applications for cancer therapy. This review presents the current knowledge on the practical applications of aptamers in the treatment of a variety of cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.7178

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 134

Metadata

Authors
Zhou, G., Wilson, G., Hebbard, L., Duan, W., Liddle, C., George, J., & Qiao, L.
Venue
Oncotarget
Published
2016-02-03
Volume
7
Issue
12
Pages
13446-13463
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2306330132
Cited by
134
References
4
FWCI
5.87
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aptamers: A promising chemical antibody for cancer therapy. https://app.cochat.ai/papers/10.18632/oncotarget.7178
The paper
Zhou, G., Wilson, G., Hebbard, L., Duan, W., Liddle, C., George, J., & Qiao, L. (2016). Aptamers: A promising chemical antibody for cancer therapy. Oncotarget. https://doi.org/10.18632/oncotarget.7178

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.